1. Home
  2. MURA vs CELU Comparison

MURA vs CELU Comparison

Compare MURA & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MURA
  • CELU
  • Stock Information
  • Founded
  • MURA 2013
  • CELU 2016
  • Country
  • MURA Ireland
  • CELU United States
  • Employees
  • MURA N/A
  • CELU N/A
  • Industry
  • MURA
  • CELU Biotechnology: Pharmaceutical Preparations
  • Sector
  • MURA
  • CELU Health Care
  • Exchange
  • MURA Nasdaq
  • CELU Nasdaq
  • Market Cap
  • MURA 57.2M
  • CELU 50.4M
  • IPO Year
  • MURA N/A
  • CELU N/A
  • Fundamental
  • Price
  • MURA $4.00
  • CELU $2.30
  • Analyst Decision
  • MURA Strong Buy
  • CELU
  • Analyst Count
  • MURA 4
  • CELU 0
  • Target Price
  • MURA $16.00
  • CELU N/A
  • AVG Volume (30 Days)
  • MURA 239.2K
  • CELU 89.6K
  • Earning Date
  • MURA 11-13-2024
  • CELU 12-06-2024
  • Dividend Yield
  • MURA N/A
  • CELU N/A
  • EPS Growth
  • MURA N/A
  • CELU N/A
  • EPS
  • MURA N/A
  • CELU N/A
  • Revenue
  • MURA N/A
  • CELU $48,200,000.00
  • Revenue This Year
  • MURA N/A
  • CELU N/A
  • Revenue Next Year
  • MURA N/A
  • CELU $233.89
  • P/E Ratio
  • MURA N/A
  • CELU N/A
  • Revenue Growth
  • MURA N/A
  • CELU 225.94
  • 52 Week Low
  • MURA $2.87
  • CELU $1.30
  • 52 Week High
  • MURA $5.62
  • CELU $7.97
  • Technical
  • Relative Strength Index (RSI)
  • MURA 66.06
  • CELU 52.94
  • Support Level
  • MURA $3.55
  • CELU $2.04
  • Resistance Level
  • MURA $4.05
  • CELU $2.39
  • Average True Range (ATR)
  • MURA 0.24
  • CELU 0.17
  • MACD
  • MURA 0.07
  • CELU 0.02
  • Stochastic Oscillator
  • MURA 91.35
  • CELU 70.76

About MURA Mural Oncology plc

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.

Share on Social Networks: